JP Morgan Initiates Coverage On Surgery Partners with Neutral Rating, Announces Price Target of $50
JP Morgan initiates coverage on Surgery Partners (NASDAQ:SGRY) with a Neutral rating and announces Price Target of $50.
SVB Leerink Initiates Coverage On Surgery Partners with Outperform Rating, Announces Price Target of $50
SVB Leerink analyst Whit Mayo initiates coverage on Surgery Partners (NASDAQ:SGRY) with a Outperform rating and announces Price Target of $50.
Cowen & Co. Initiates Coverage On Surgery Partners with Market Perform Rating, Announces Price Target of $50
Cowen & Co. analyst Gary Taylor initiates coverage on Surgery Partners (NASDAQ:SGRY) with a Market Perform rating and announces Price Target of $50.
Surgery Partners: Q2 Earnings Insights
Shares of Surgery Partners (NASDAQ:SGRY) fell 0.7% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 100.00% over the past year to $0.00, which beat the estimate of ($0.20).
Surgery Partners Q2 EPS $0.00 Beat $(0.20) Est., Sales $543.30M Beat $538.30M Estimate
Surgery Partners (NASDAQ:SGRY) reported quarterly sales of $543.30 million which beat the analyst consensus estimate of $538.30 million by 0.93 percent. This is a 45.00 percent increase over sales of $374.70 million the
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
